Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
35.78
-0.33 (-0.91%)
Jul 23, 2026, 10:38 AM EDT - Market open
Neurogene Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
131
Market Cap
712.98M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 925.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 299.77M |
| Zevra Therapeutics | 122.29M |
| CytomX Therapeutics | 35.54M |
| Aclaris Therapeutics | 8.37M |
| Oculis Holding AG | 1.40M |
NGNE News
- 16 days ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 22 days ago - Neurogene prices 3.5M shares at $30.00 in public offering - TheFly
- 22 days ago - Neurogene Inc. Announces Pricing of $125 Million Public Offering - Business Wire
- 22 days ago - Neurogene 75M Spot Secondary; re-offered at $30.00 - TheFly
- 22 days ago - Neurogene announces common stock offering, no amount given - TheFly
- 22 days ago - Neurogene Inc. Announces Proposed Public Offering - Business Wire
- 24 days ago - Neurogene Transcript: Study result - Transcripts
- 24 days ago - Neurogene Press release: Study result - Filings